Mecamylamine-precipitated nicotine withdrawal syndrome and its prevention with baclofen: An autoradiographic study of α4β2 nicotinic acetylcholine receptors in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 44, Issue , 2013, Pages 217-225

  Varani, Andrés P ^a   Antonelli, Marta C ^b   Balerio, Graciela N ^a,b  

^a Instituto de Investigaciones Farmacologicas   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

4 2 nicotinic receptor; 3H epibatidine; Acb; BAC; Baclofen; BST; CPu; Cx; DLG; Fr; IP; MEC; MHb; NAChRs; NIC; Nicotine; PAG; SAL; SN; VTA; Withdrawal

Indexed keywords

BACLOFEN; EPIBATIDINE; EPIBATIDINE H 3; MECAMYLAMINE; NICOTINE; NICOTINIC RECEPTOR ALPHA4BETA2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING SITE; BRAIN; BRAIN MAPPING; BRAIN REGION; CONTROLLED STUDY; HABENULA; HABENULOINTERPEDUNCULAR TRACT; INTERPEDUNCULAR NUCLEUS; LATERAL GENICULATE BODY; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; SUPERIOR COLLICULUS; THALAMUS NUCLEUS; VENTRAL TEGMENTUM; WITHDRAWAL SYNDROME;

ANALYSIS OF VARIANCE; ANIMALS; AUTORADIOGRAPHY; BACLOFEN; BRAIN; CHOLINERGIC AGENTS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GABA-B RECEPTOR AGONISTS; MALE; MECAMYLAMINE; MICE; NICOTINIC ANTAGONISTS; RECEPTORS, NICOTINIC; TIME FACTORS; TOBACCO USE DISORDER; TRITIUM;

EID: 84875801554     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.02.016     Document Type: Article

References (90)

1. 3H]ouabain in cerebral cortex of rabbit brain using quantitative autoradiography. J Neurochem 1989, 52:193-200.
2. Baddick C.G., Marks M.J. An autoradiographic survey of mouse brain nicotinic acetylcholine receptors defined by null mutants. Biochem Pharmacol 2011, 82:828-841.
3. Baldwin P.R., Alanis R., Salas R. The role of the habenula in nicotine addiction. J Addict Res Ther 2011, S1(2). [pii: 002].
4. Balerio G.N., Rubio M.C. Baclofen analgesia: involvement of the GABAergic system. Pharmacol Res 2002, 46:281-286.
5. Balerio G.N., Aso E., Berrendero F., Murtra P., Maldonado R. δ9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. Eur J Neurosci 2004, 20:2737-2748.
6. Balfour D.J.K. The neuronal pathways mediating the behavioral and addictive properties of nicotine. Handb Exp Pharmacol 2009, 192:209-233. J.E. Henningfield (Ed.).
7. Bencherif M., Fowler K., Lukas R.J., Lippiello P.M. Mechanisms of up-regulation of neuronal nicotinic acetylcholine receptors in clonal cell lines and primary cultures of fetal rat brain. J Pharmacol Exp Ther 1995, 275:987-994.
8. Benowitz N.L. Nicotine addiction. N Engl J Med 2010, 362:2295-2303.
9. B receptor site distribution in the rat central nervous system. Neuroscience 1987, 20:365-383.
10. Brody A.L. Functional brain imaging of tobacco use and dependence. J Psychiatr Res 2006, 40:404-418.
11. Buisson B., Bertrand D. Chronic exposure to nicotine upregulates the human α4β2 nicotinic acetylcholine receptor function. J Neurosci 2001, 21:1819-1829.
12. Buisson B., Bertrand D. Nicotine addiction: the possible role of functional upregulation. Trends Pharmacol Sci 2002, 23:130-136.
13. Champtiaux N., Gotti C., Cordero-Erausquin M., David D.J., Przybylski C., Léna C., et al. Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J Neurosci 2003, 23:7820-7829.
14. Changeux J.P. Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. Nat Rev Neurosci 2010, 11:389-401.
15. Corrigall W.A., Coen K.M., Adamson K.L., Chow J.Z. Response of nicotine self-administration in the rat to manipulations of mu-opioid and γ-aminobutyric acid receptors in the ventral tegmental area. Psychopharmacology (Berl) 2000, 149:107-114.
16. (B) receptor agonist baclofen on cigarette smoking and nicotine craving. College on Problems of Drug Dependence 62nd Annual Meeting 2000, 32.
17. Cox C.L., Sherman S.M. Control of dendritic outputs of inhibitory interneurons in the lateral geniculate nucleus. Neuron 2000, 27:597-610.
18. Damaj M.I., Siu E.C., Sellers E.M., Tyndale R.F., Martin B.R. Inhibition of nicotine metabolism by methoxysalen: pharmacokinetic and pharmacological studies in mice. J Pharmacol Exp Ther 2007, 320:250-257.
19. Davis J.A., Gould T.J. Hippocampal nAChRs mediate nicotine withdrawal-related learning deficits. Eur Neuropsychopharmacol 2009, 19:551-561.
20. De Biasi M., Dani J.A. Reward, addiction, withdrawal to nicotine. Annu Rev Neurosci 2011, 34:105-130.
21. De Biasi M., Salas R. Influence of neuronal nicotinic receptors over nicotine addiction and withdrawal. Exp Biol Med (Maywood) 2008, 233:917-929.
22. Decker M.W., Brioni J.D., Bannon A.W., Arneric S.P. Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics. Life Sci 1995, 56:545-570.
23. Diaz S.L., Kemmling A.K., Rubio M.C., Balerio G.N. Lack of sex-related differences in the prevention by baclofen of the morphine withdrawal syndrome in mice. Behav Pharmacol 2001, 12:75-79.
24. Diaz S.L., Kemmling A.K., Balerio G.N. Baclofen reestablishes striatal and cortical dopamine concentrations during naloxone-precipitated withdrawal. Neurochem Int 2003, 42:293-298.
25. Diaz S.L., Kemmling A.K., Bonavita C.D., Rubio M.C., Balerio G.N. Baclofen reestablishes micro-opioid receptor levels modified by morphine withdrawal syndrome in either sex. Synapse 2004, 54:24-29.
26. Diaz S.L., Barros V.G., Antonelli M.C., Rubio M.C., Balerio G.N. Morphine withdrawal syndrome and its prevention with baclofen: autoradiographic study of mu-opioid receptors in prepubertal male and female mice. Synapse 2006, 60:132-140.
27. Eapen M., Zald D.H., Gatenby J.C., Ding Z., Gore J.C. Using high-resolution MR imaging at 7T to evaluate the anatomy of the midbrain dopaminergic system. AJNR Am J Neuroradiol 2011, 32:688-694.
28. Even N., Cardona A., Soudant M., Corringer P.J., Changeux J.P., Cloëz-Tayarani I. Regional differential effects of chronic nicotine on brain alpha 4-containing and alpha 6-containing receptors. Neuroreport 2008, 19:1545-1550.
29. Fattore L., Spano M.S., Cossu G., Scherma M., Fratta W., Fadda P. Baclofen prevents drug-induced reinstatement of extinguished nicotine-seeking behaviour and nicotine place preference in rodents. Eur Neuropsychopharmacol 2009, 19:487-498.
30. Fenster C.P., Rains M.F., Noerager B., Quick M.W., Lester R.A. Influence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of nicotine. J Neurosci 1997, 17:5747-5759.
31. B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend 2009, 103:30-36.
32. Fung Y.K., Schimid M.J., Anderson T.M., Lau Y. Effects of nicotine withdrawal on central dopaminergic systems. Pharmacol Biochem Behav 1996, 53:635-640.
33. Gäddnäs H., Pietilä K., Ahtee L. Effects of chronic oral nicotine treatment and its withdrawal on locomotor activity and brain monoamines in mice. Behav Brain Res 2000, 113:65-72.
34. Gotti C., Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 2004, 74:363-396.
35. Gotti C., Moretti M., Clementi F., Riganti L., McIntosh J.M., Collins A.C., et al. Expression of nigrostriatal alpha 6 containing nicotinic acetylcholine receptors is selectively reduced, but not eliminated, by beta 3 subunit gene deletion. Mol Pharmacol 2005, 67:2007-2015.
36. Gotti C., Moretti M., Zanardi A., Gaimarri A., Champtiaux N., Changeux J.P., et al. Heterogeneity and selective targeting of neuronal nicotinic acetylcholine receptor (nAChR) subtypes expressed on retinal afferents of the superior colliculus and lateral geniculate nucleus: identification of a new native nAChR subtype alpha3beta2 (alpha5 or beta3) enriched in retinocollicular afferents. Mol Pharmacol 2005, 68:1162-1171.
37. Gould T.J., Portugal G.S., André J.M., Tadman M.P., Marks M.J., Kenney J.W., et al. The duration of nicotine withdrawal-associated deficits in contextual fear conditioning parallels changes in hippocampal high affinity nicotinic acetylcholine receptor upregulation. Neuropharmacology 2012, 62:2118-2125.
38. Govind A.P., Vezina P., Green W.N. Nicotine-induced upregulation of nicotinic receptors: underlying mechanisms and relevance to nicotine addiction. Biochem Pharmacol 2009, 78:756-765.
39. Grady S.R., Wageman C.R., Patzlaff N.E., Marks M.J. Low concentrations of nicotine differentially desensitize nicotinic acetylcholine receptors that include α5 or α6 subunits and that mediate synaptosomal neurotransmitter release. Neuropharmacology 2012, 62:1935-1943.
40. Grilli M., Zappettini S., Raiteri L., Marchi M. Nicotinic and muscarinic cholinergic receptors coexist on GABAergic nerve endings in the mouse striatum and interact in modulating GABA release. Neuropharmacology 2009, 56:610-614.
41. Guo J.Z., Tredway T.L., Chiappinelli V.A. Glutamate and GABA release are enhanced by different subtypes of presynaptic nicotinic receptors in the lateral geniculate nucleus. J Neurosci 1998, 18:1963-1969.
42. Guo J.Z., Liu Y., Sorenson E.M., Chiappinelli V.A. Synaptically released and exogenous ACh activates different nicotinic receptors to enhance evoked glutamatergic transmission in the lateral geniculate nucleus. J Neurophysiol 2005, 94:2549-2560.
43. Hilario M.R., Turner J.R., Blendy J.A. Reward sensitization: effects of repeated nicotine exposure and withdrawal in mice. Neuropsychopharmacology 2012, 37:2661-2670.
44. Hildebrand B.E., Nomikos G.G., Hertel P., Schilström B., Svensson T.H. Reduce dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res 1998, 779:214-225.
45. Hsu Y.N., Amin J., Weiss D.S., Wecker L. Sustained nicotine exposure differentially affects α3β2 and α4β2 neuronal nicotinic receptors expressed in Xenopus oocytes. J Neurochem 1996, 66:667-675.
46. Huang L.Z., Winzer-Serhan U.H. Chronic neonatal nicotine upregulates heteromeric nicotinic acetylcholine receptor binding without change in subunit mRNA expression. Brain Res 2006, 1113:94-109.
47. Hyman S.E., Malenka R.C., Nestler E.J. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 2006, 29:565-598.
48. Klemm W.R. Habenular and interpeduncularis nuclei: shared components in multiple-function networks. Med Sci Monit 2004, 10:RA261-RA273.
49. Lecourtier L., Kelly P.H. A conductor hidden in the orchestra? Role of the habenular complex in monoamine transmission and cognition. Neurosci Biobehav Rev 2007, 31:658-672.
50. Lu Y., Grady S., Marks M.J., Picciotto M., Changeux J.P., Collins A.C. Pharmacological characterization of nicotinic receptor-stimulated GABA release from mouse brain synaptosomes. J Pharmacol Exp Ther 1998, 287:648-657.
51. Malin D.H., Goyarzu P. Rodent models of nicotine withdrawal syndrome. Handb Exp Pharmacol 2009, 192:401-434.
52. Marks M.J., Burch J.B., Collins A.C. Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J Pharmacol Exp Ther 1983, 226:817-825.
53. Marks M.J., Pauly J.R., Gross S.D., Deneris E.S., Hermans B.I., Heinemann S.F., et al. Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J Neurosci 1992, 12:2765-2784.
54. Marks M.J., Smith K.W., Collins A.C. Differential agonist inhibition identifies multiple epibatidine binding sites in mouse brain. J Pharmacol Exp Ther 1998, 285:377-386.
55. 125I]-epibatidine binding sites in C57BL/6 mouse brain are differentially affected by chronic nicotine treatment. Neuropharmacology 2004, 46:1141-1157.
56. Marks M.J., Whiteaker P., Collins A.C. Deletion of the alpha7, beta2, or beta4 nicotinic receptor subunit genes identifies highly expressed subtypes with relatively low affinity for [3H]epibatidine. Mol Pharmacol 2006, 70:947-959.
57. Marks M.J., McClure-Begley T.D., Whiteaker P., Salminen O., Brown R.W., Cooper J., et al. Increased nicotinic acetylcholine receptor protein underlies chronic nicotine-induced up-regulation of nicotinic agonist binding sites in mouse brain. J Pharmacol Exp Ther 2011, 337:187-200.
58. Matsumoto M., Hikosaka O. Lateral habenula as a source of negative reward signals in dopamine neurons. Nature 2007, 447:1111-1115.
59. Matta S.G., Balfour D.J., Benowitz N.L., Boyd R.T., Buccafusco J.J., Caggiula A.R., et al. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) 2007, 190:269-319.
60. 3H]GABA release from mouse brain synaptosomes is modulated by alpha4beta2 and alpha4alpha5beta2 nicotinic receptor subtypes. Mol Pharmacol 2009, 75:918-926.
61. Metaxas A., Bailey A., Barbano M.F., Galeote L., Maldonado R., Kitchen I. Differential region-specific regulation of α4β2* nAChRs by self-administered and non-contingent nicotine in C57BL/6J mice. Addict Biol 2010, 15:464-479.
62. Millar N.S., Gotti C. Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology 2009, 56:237-246.
63. Nashmi R., Xiao C., Deshpande P., McKinney S., Grady S.R., Whiteaker P., et al. Chronic nicotine cell specifically upregulates functional alpha 4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path. J Neurosci 2007, 27:8202-8218.
64. Nomikos G.G., Hildebrand B.E., Panagis G., Svensson T.H. Nicotine withdrawal in the rat: role of alpha7 nicotinic receptors in the ventral tegmental area. Neuroreport 1999, 10:697-702.
65. Olale F., Gerzanich V., Kuryatov A., Wang F., Lindstrom J. Chronic nicotine exposure differentially affects the function of human α3, α4, and α7 neuronal nicotinic receptor subtypes. J Pharmacol Exp Ther 1997, 283:675-683.
66. Paolini M., De Biasi M. Mechanistic insights into nicotine withdrawal. Biochem Pharmacol 2011, 82:996-1007.
67. Paterson D., Nordberg A. Neuronal nicotinic receptors in the human brain. Prog Neurobiol 2000, 61:75-111.
68. Pauly J.R., Marks M.J., Robinson S.F., van de Kamp J.L., Collins A.C. Chronic nicotine and mecamylamine treatment increase brain nicotinic receptor binding without changing alpha 4 or beta 2 mRNA levels. J Pharmacol Exp Ther 1996, 278:361-369.
69. Paxinos G., Franklin K. The mouse brain in stereotaxic coordinates 2004, Academic Press, London. second ed.
70. Peltopuro P., Kala K., Partanen J. Distinct requirements for Ascl1 in subpopulations of midbrain GABAergic neurons. Dev Biol 2010, 343:63-70.
71. Peng X., Gerzanich V., Anand R., Whiting P.J., Lindstrom J. Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. Mol Pharmacol 1994, 46:523-530.
72. Ribeiro-Carvalho A., Lima C.S., Medeiros A.H., Siqueira N.R., Filgueiras C.C., Manhães A.C., et al. Combined exposure to nicotine and ethanol in adolescent mice: effects on the central cholinergic systems during short and long term withdrawal. Neuroscience 2009, 162:1174-1186.
73. Salas R., Pieri F., De Biasi M. Decreased signs of nicotine withdrawal in mice null for the beta4 nicotinic acetylcholine receptor subunit. J Neurosci 2004, 24:10035-10039.
74. Salas R., Sturm R., Boulter J., De Biasi M. Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice. J Neurosci 2009, 29:3014-3018.
75. (B) receptors in the dystonic hamster: pronounced antidystonic effects of baclofen after striatal injections. Neuroscience 2009, 162:423-430.
76. SENASA Requisitos, condiciones y procedimientos para la habilitación técnica de laboratorios que posean bioterios de producción, mantenimiento y local de experimentación Resolución 617/2002.
77. Slotkin T.A., Seidler F.J. A unique role for striatal serotonergic systems in the withdrawal from adolescent nicotine administration. Neurotoxicol Teratol 2007, 29:10-16.
78. Slotkin T.A., Ryde I.T., Seidler F.J. Separate or sequential exposure to nicotine prenatally and in adulthood: persistent effects on acetylcholine systems in rat brain regions. Brain Res Bull 2007, 74:91-103.
79. Small E., Shah H.P., Davenport J.J., Geier J.E., Yavarovich K.R., Yamada H., et al. Tobacco smoke exposure induces nicotine dependence in rats. Psychopharmacology (Berl) 2010, 208:143-158.
80. Sokolova E., Matteoni C., Nistri A. Desensitization of neuronal nicotinic receptors of human neuroblastoma SH-SY5Y cells during short or long exposure to nicotine. Br J Pharmacol 2005, 146:1087-1095.
81. Stolerman I.P., Jarvis M.J. The scientific case that nicotine is addictive. Psychopharmacology (Berl) 1995, 117:2-10.
82. Traynor J.R. Epibatidine and pain. Br J Anaesth 1998, 81:69-76.
83. Turner J.R., Castellano L.M., Blendy J.A. Parallel anxiolytic- like effects and upregulation of neuronal nicotinic acetylcholine receptors following chronic nicotine and varenicline. Nicotine Tob Res 2011, 13:41-46.
84. B receptors involvement in the effects induced by nicotine on anxiety-related behaviour in mice. Behav Pharmacol 2012, 65:507-513.
85. Varani A.P., Moutinho L.M., Calvo M., Balerio G.N. Ability of baclofen to prevent somatic manifestations and neurochemical changes during nicotine withdrawal. Drug Alcohol Depend 2011, 119:5-12.
86. (B1) knockout mice. Neuropharmacology 2012, 63:863-872.
87. Wecker L., Pollock V.V., Pacheco M.A., Pastoor T. Nicotine-induced up regulation of α4β2 neuronal nicotinic receptors is mediated by the protein kinase C-dependent phosphorylation of α4 subunits. Neuroscience 2010, 171:12-22.
88. Whiteaker P., Marks M.J., Grady S.R., Lu Y., Picciotto M.R., Changeux J.P., et al. Pharmacological and null mutation approaches reveal nicotinic receptor diversity. Eur J Pharmacol 2000, 393:123-135.
89. Wong M.L., Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci 2001, 2:343-351.
90. B receptors in mammalian brain: potential targets for drug development. Drug Dev Res 1990, 21:161-167.